RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Gilead Sciences Inc.

A collection of news and information related to Gilead Sciences Inc. published by this site and its partners.

Top Gilead Sciences Inc. Articles

Displaying items 1-11
  • Biotech stocks rout beginning to reveal pockets of value

    NEW YORK (Reuters) - Predicting when the bear market in biotech stocks will hit bottom is a hazardous prospect, but one gauge that factors in the rapid profit growth estimates for many of these companies suggests several are starting to look attractive....
  • The $84,000 hepatitis drug [Letter]

    It was interesting to read that there is now a cure for hepatitis C in the form of new drugs that are capable of completely suppressing the virus in 90 percent of patients in 8 to 12 weeks ("Gilead Sciences' $84,000 price for hepatitis drug is...
  • J&J beats forecasts as sales of new drugs shine

    (Reuters) - Johnson & Johnson reported quarterly earnings well above expectations, as strong sales of new drugs offset weak demand for consumer products and medical devices, and the company slightly raised its full-year profit view. J&J on Tuesday said...
  • U.S. healthcare usage and spending resumes rise in 2013: report

    U.S. healthcare usage and spending resumes rise in 2013: report
    Americans used more health services and spent more on prescription drugs in 2013, reversing a recent trend, though greater use of cheaper generic drugs helped control spending, according to a report issued on Tuesday by a leading healthcare information...
  • New drugs provide cure for hepatitis C, research finds

    Twenty-five years after scientists first identified the hepatitis C virus, doctors are declaring victory over an infection that afflicts more than 3 million Americans and kills more of them than HIV. In a series of clinical trial results, a new...
  • Texas Medicaid holds off on proposed limits for Gilead hepatitis drug

    (Reuters) - Texas is reconsidering whether to impose strict limits on Gilead Sciences' $84,000 hepatitis C treatment for patients on the state's Medicaid health plan for the poor, at the urging of outside advisers, a state official said on Friday. The...
  • Nasdaq plunges on tech stock sell-off

     Nasdaq plunges on tech stock sell-off
    A plunge in once-soaring technology shares sent Nasdaq into a triple-digit decline and yanked the rest of the stock market down with it. Erstwhile darlings such as Netflix Inc. and Facebook Inc., as well as biotechnology highfliers such as Intercept...
  • Doctors welcome hepatitis C drug rivals, Gilead still leads

    LOS ANGELES/LONDON (Reuters) - Doctors at a key medical conference welcomed the prospect of more new drugs to treat the liver-destroying hepatitis C virus, while agreeing that Gilead Sciences Inc continues to lead the effort. Gilead, under fire from...
  • U.S. drug industry group defends price of Gilead hepatitis drug

    WASHINGTON (Reuters) - The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-...
  • Natco seeks to block Gilead's hepatitis C drug patent in India: source

    MUMBAI (Reuters) - India's Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc's new hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said. If successful, the...
  • Bristol-Myers hepatitis C treatment cures up to 90 percent: study

    (Reuters) - A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage...